New study compares the effects of low-level red light with 0.01% atropine treatment on axial length and choroid in myopic children

Published on August 13, 2025
Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.
Continue reading on website
Other news

Study finds electroretinography/pupillometry as strongest predictor of DR progression, vision-threatening complications

August 13, 2025
Data used in the post-hoc analysis was from 56 parameters from 4 testing modalities obtained in a multi-center US trial (NCT03197870).

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Product Pipeline Updates

August 14, 2025
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, yesterday announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. Net loss for the second quarter of 2